Search

Made available in DSpace on 2022-04-29T02:43:34Z (GMT). No. of bitstreams: 0 Previous issue date: 2012-03-07 Painful bladder syndrome associated with interstitial cystitis (PBS/IC) is a clinical condition characterized pelvic pain, urinary urgency, and urinary frequency. In this study, 22 patients were assigned to make two visits over a three weeks period. The patients were randomly, double-blinded assigned in two groups. The first group received Cystex® capsules. The second group received placebo capsules. Two capsules were taken three times a day away from meals. The change from baseline in the O'Leary-Sant IC symptom and problem index was the primary outcome parameter. Changes in functional bladder capacity and intensity of pain and urgency have been chosen as secondary outcome parameters. Mood as well as physical and sexual activity were rated by 10 questions on a scale 0 to 6. The ratings were analyzed and the average for each patient in both groups Cystex® and placebo was determined as the quality of life index. For the primary outcome there was a statistically significant difference between the groups. Mean symptom score-sum decreased from 28.4 to 20.5 in the Cystex® group compared with 29.5 to 26.8 in the placebo group (p0.05). In our study, Cystex® enhanced quality of life over the placebo showing a statistically significant. This trial have shown that the efficacy and safety of therapy with Cystex® in the treatment of interstitial cystitis and is an alternative for patients suffering from this pathology. Therefore, it can be concluded that the composition of Cystex®, increased the quality of life in treated patients. Laboratório de Farmacognosia, Escola de Farmácia Departamento de Farmácia Universidade Federal de Ouro Preto, Minas Gerais Faculdade de Filosofia e Ciências Departamento de Fonoaudiologia Universidade Estadual Paulista, São Paulo Departamento de Farmácia Centro Universitário Fundação Instituto de Ensino para Osasco, Osasco Departamento de Ciências Biológicas Campus Diadema Universidade Federal de São Paulo, Diadema Laboratório de Pesquisa em Fármacos Universidade Federal do Amapá, Macapá, Amapá Departamento de Ciências Exatas e da Terra Campus Diadema Universidade Federal de São Paulo Faculdade de Filosofia e Ciências Departamento de Fonoaudiologia Universidade Estadual Paulista, São Paulo

Made available in DSpace on 2015-02-24T13:58:06Z (GMT). No. of bitstreams: 0 Previous issue date: 2012Bitstream added on 2015-02-24T14:07:57Z : No. of bitstreams: 1 ISSN18402291-2012-06-02-423-427.pdf: 363196 bytes, checksum: ed13beec9cccc4d76ff46ec242ed1ea4 (MD5) Painful bladder syndrome associated with interstitial cystitis (PBS/IC) is a clinical condition characterized pelvic pain, urinary urgency, and urinary frequency. In this study, 22 patients were assigned to make two visits over a three weeks period. The patients were randomly, double-blinded assigned in two groups. The first group received Cystex® capsules. The second group received placebo capsules. Two capsules were taken three times a day away from meals. The change from baseline in the O’Leary-Sant IC symptom and problem index was the primary outcome parameter. Changes in functional bladder capacity and intensity of pain and urgency have been chosen as secondary outcome parameters. Mood as well as physical and sexual activity were rated by 10 questions on a scale 0 to 6. The ratings were analyzed and the average for each patient in both groups Cystex® and placebo was determined as the quality of life index. For the primary outcome there was a statistically significant difference between the groups. Mean symptom score-sum decreased from 28.4 to 20.5 in the Cystex® group compared with 29.5 to 26.8 in the placebo group (p0.05). In our study, Cystex® enhanced quality of life over the placebo showing a statistically significant. This trial have shown that the efficacy and safety of therapy with Cystex® in the treatment of interstitial cystitis and is an alternative for patients suffering from this pathology. Therefore, it can be concluded that the composition of Cystex®, increased the quality of life in treated patients. Universidade Estadual Paulista Júlio de Mesquita Filho, Departamento de Fonoaudiologia, Faculdade de Filosofia e Ciências - Campus de Marília, Marilia, Avenida Hygino Muzzi Filho, 737. Caixa Postal 181., Campus Universitário, CEP 17525-900, SP, Brasil Universidade Estadual Paulista Júlio de Mesquita Filho, Departamento de Fonoaudiologia, Faculdade de Filosofia e Ciências - Campus de Marília, Marilia, Avenida Hygino Muzzi Filho, 737. Caixa Postal 181., Campus Universitário, CEP 17525-900, SP, Brasil